Clazakizumab to lower immune damage after lung transplant
Targeting Inflammation and Alloimmunity in Lung Transplant Recipients With Clazakizumab
This project gives the drug clazakizumab to people who have had a lung transplant to try to reduce harmful inflammation and prevent rejection.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11120969 on NIH RePORTER |
What this research studies
If you have had a lung transplant, this project would give clazakizumab, a medicine that blocks the inflammatory signal IL-6, early after transplant. You would be followed with regular clinic visits, blood tests for donor-specific antibodies and immune cell changes, and lung function checks to see if inflammation and rejection are reduced. The team will also look at tissue and immune markers to understand how the drug changes the immune response that leads to chronic lung graft damage. The goal is to link these immune changes to how your lungs are doing over time.
Who could benefit from this research
Good fit: Ideal candidates are adults who have recently received a lung transplant, especially those at higher risk for antibody-mediated rejection or early inflammatory complications.
Not a fit: People without a lung transplant, those with long-standing, advanced chronic lung allograft dysfunction, or patients who cannot receive additional immunomodulatory therapy are unlikely to benefit.
Why it matters
Potential benefit: If successful, the treatment could lower rejection, protect the transplanted lung from chronic damage, and improve long-term survival and lung function.
How similar studies have performed: Blocking IL-6 helped reduce harmful antibodies and improved outcomes in some kidney transplant patients and animal studies show benefit, but this approach is newer for lung transplant care.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Madsen, Joren C — Massachusetts General Hospital
- Study coordinator: Madsen, Joren C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.